Introduction
Giant cell tumor of bone (GCTB; or osteoclastoma) is an uncommon, benign, osteolytic neoplasm. GCTB comprises 3 to 5% of all primary bone tumors and occurs predominantly in early adulthood (peak incidence ages, 20-40 years) with a slight female predominance (3:2). [1] [2] [3] These tumors are thought to originate from neoplastic nonosteogenic stromal cells of the bone marrow and are characterized histologically by numerous multinucleated osteoclastic giant cells diffusely distributed among a background of mononuclear stromal and macrophage lineage cells. 1,4-6 GCTB most commonly affects the epiphyses of long bones, particularly of the distal femur and proximal tibia. 6 Patients classically present with a combination of pain, swelling, or pathologic fracture at the tumor origin. 7 Although regarded as benign, GCTB can recur locally following en bloc surgical resection. 8, 9 In 2 to 3% of cases, GCTBs can hematogenously metastasize to the lungs, resulting in benign pulmonary implants with rare malignant transformation. 9, 10 Despite an improved understanding of the molecular and cellular biology underlying the GCTB pathogenesis, the behavior of this tumor is often heterogeneous and can be difficult to predict on the basis of clinical, radiographic, or histologic features. Although involvement of the appendicular skeleton is more typical for GCTB, axial skeleton involvement, especially of the cranial and facial bones, has also been reported and is becoming increasingly appreciated in the literature. Approximately 2% of GCTBs involve the head and neck. [11] [12] [13] Involvement of the axial skeleton is often associated with increased morbidity because of local infiltration of critical structures and the associated difficulty of complete tumor resection, particularly compared with resection of GCTBs of the appendicular skeleton. 8, 14 GCTB of the skull has also been reported to behave in a locally aggressive fashion.
with en bloc or wide local excision portending the lowest risk of recurrence and best clinical outcomes in patients.
4,16
Although much research has focused on GCTBs involving the long bones, numerous studies have also reported on GCTBs involving the lateral skull base. Here, we review other reported cases of GCTBs involving the lateral skull base and report on the clinical presentation, radiographic findings, neurosurgical management, and outcome of a patient with a GCTB of the middle and infratemporal fossae.
Methods
A literature search was performed using the PubMed/Medline database for cases of GCTB of the lateral skull base. The literature search spanned articles published between 1970 and June 2017. The keywords utilized in the search included: "giant cell tumor of bone," "GCTB," "GCT," "osteoclastoma," "lateral skull base," and "skull base tumor." The list of publications was reviewed for articles with relevance to our study (i.e., reports of GCTB of the lateral skull base).
Full-text articles in the English language were reviewed and chosen based on whether they included a reported case of a patient with a GCTB involving the lateral skull base.
Case Report History and Examination
A 22-year-old man presented to the neurosurgical service after sustaining a traumatic brain injury when he was hit by a vehicle while riding his bike without a helmet. The patient experienced a brief loss of consciousness at the scene and reported a nonfluctuating headache. He was taken to an outside hospital, where a noncontrast head computed tomography (CT) scan demonstrated a left temporal intraparenchymal hemorrhage, left temporal bone fractures, multiple facial bone fractures, and an incidental lytic bone mass of the left lateral skull base (►Fig. 1). The patient was transferred to our institution for further evaluation. Upon additional history gathering, the patient reported decreased hearing in the left ear over several months, as well as a recent slight bulging of his left face. On examination, the patient was awake, alert, and oriented to person and place. Cranial nerves were grossly intact, except for diminished sensorineural hearing in his left ear. Motor and sensory examinations were grossly intact throughout. He underwent diagnostic magnetic resonance imaging (MRI), which revealed a large tumor extending from the middle cranial fossa into the infratemporal fossa, with an associated intraparenchymal hemorrhage involving the left temporal lobe (►Fig. 2). Given this finding, the patient was taken to the operative theater for tumor resection.
Operative and Postoperative Course
The patient was positioned supine and secured in a Mayfield frame for microsurgical resection of the lesion. Given the infratemporal extension of the tumor, a Fisch-type approach was utilized, with a preauricular incision providing access to the infratemporal and intracranial components of this neoplasm. After elevation of the temporalis muscle, the tumor was found to be intimately involved with the bony structures. Frozen and eventual final pathology samples were consistent with a giant cell tumor without malignant features (►Fig. 3). Accordingly, a gross total resection of the tumor with negative margins was performed.
The temporal bone was drilled thoroughly with sacrifice of the left vestibulocochlear nerve to attain adequate margins. The left facial nerve was identified and skeletonized to protect and preserve function. Tumor-infiltrated temporal, frontal, and zygomatic bones were removed. Tumor feeding vessels arising from the superficial and deep temporal arteries were coagulated to devascularize the tumor. Normal bony margins were obtained. With respect to the intracranial compartment, tumor involving the dura was resected. In addition, upon reflection of the dura, the tumor was found to involve the left lateral temporal lobe, causing hemorrhage and mass effect. The left temporal lobe involved by the tumor was surgically resected.
At the completion of the procedure, the facial nerve was stimulated to ensure its integrity, and meticulous hemostasis was obtained. To repair the skull base defect, mesh cranioplasty with polymethyl methacrylate was fashioned to a normal cranial contour. A small amount of superficial fat was placed into the site of the defect. MRI demonstrated complete removal of the tumor in this patient (►Fig. 4). Postoperatively, the patient had nonserviceable hearing in the left ear, but was otherwise neurologically intact, including preservation of the facial nerve function, and was discharged home on postoperative day 5. No adjuvant radiation was planned. At the 3-month follow-up, the patient was neurologically intact but did require cerebrospinal fluid diversion for a hygroma.
Results ►Table 1 summarizes the cases of tumors involving the lateral skull base identified in our review of the English language literature. Including our case, a total of 94 patients with GCTBs of the lateral skull base were identified through our review. As an aggregate, 56% of patients were male (53/94), while 44% were female (41/94). The mean age at presentation was 36.8 years (range: 0.17-79 years). Clinical presentations were variable and included headache (33%, 29/88), hearing loss (31%, 27/88), facial/preauricular swelling (22%, 19/88), facial/ preauricular pain (17%, 15/88), tinnitus (15%, 13/88), aural fullness (10%, 9/88), diplopia (10%, 9/88), vision loss (10%, 9/88), ear pain (8%, 7/88), facial nerve palsy (8%, 7/88), proptosis (5%, 4/88), and dizziness (5%, 4/88). GCTB origin, in order of frequency, was temporal bones (62%, 58/94), sphenoid bones (32%, 30/94), occipital bones (5%, 5/94), and frontal bones (1%, 1/94).
Treatment data were reported for 91 patients. Of these patients, 52% (47/91) received gross total resections, 46% (42/ 91) subtotal resections, and 2% (2/91) did not receive treatment. Of 90 patients with clear documentation, 37% (33/90) received adjuvant radiotherapy following surgical treatment.
Of patients with reported follow-up, 14% (12/86) had local disease recurrence. In addition, of those patients with recurrence, 50% (6/12) had received subtotal resections alone, 25% (3/12) received subtotal resections with adjuvant radiotherapy, and 25% (3/12) received gross total resections alone. Of note, no patients receiving gross total resections with adjuvant radiotherapy developed recurrence (n ¼ 4).
Discussion
GCTB is considered a benign, but locally aggressive, neoplasm of bone. These tumors are thought to originate from nonosteogenic neoplastic stromal cells of the bone marrow admixed with multinucleated osteoclastic giant cells.
1,6
GCTBs most commonly affect the epiphyses of long bones, but have also been appreciated in the cranial and facial bones, including the skull base. 6 Although considered a benign lesion, GCTB has a variable natural history, with the risk of local recurrence or distant metastasis being highly unpredictable. Unlike other types of cancer, metastatic spread of GCTB does not carry similar prognostic implications. 17 Despite improved understanding of the underlying cellular and molecular biology underpinning GCTB pathogenesis, our knowledge regarding this tumor's behavioral heterogeneity remains incomplete. GCTBs of the cranial and facial bones most commonly affect the temporal and sphenoid bones. 14, 15, [18] [19] [20] GCTBs of the lateral skull base are often locally aggressive and can invade nearby critical structures. 18, 21 It is believed that these tumors arise in these areas because the bones of the mandible, sphenoid, ethmoid, and parts of the temporal bone form largely through the process of endochondral ossification.
22
In contrast, the other cranial bones (i.e., frontal and parietal bones) arise from intramembranous ossification and are less frequently affected by GCTB. 15, 22 Patients with GCTB of the temporal bone typically present with headache, conductive hearing loss, aural fullness, preauricular pain, or facial weakness. 18, 20, 23 In comparison, patients with GCTB of the sphenoid bone may present with symptoms such as headache, facial hypoesthesia, diplopia, blindness, or visual field defects.
18,19
Both CT and MRI are used to identify and characterize GCTB of the lateral skull base. On CT imaging, GCTBs usually Giant Cell Tumor of the Lateral Skull Base Gamboa et al. e46
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Surgical removal of GCTB of the skull with complete resection is the current treatment of choice. 8, 14, 18 The surgical management of GCTB of the lateral skull base can be difficult because of its proximity to critical neurovascular structures. Although gross total resection of the tumor is ideal, this may not be feasible depending on the extent of structural involvement by the tumor. In this setting, partial resection (i.e., maximal safe resection) followed by adjuvant radiotherapy may be a reasonable alternative. local control in four of five patients treated with intensitymodulated radiation therapy to a median dose of 64 Gy using conventional fractionation. There are also reports on the use of Gamma Knife (stereotactic) radiosurgery in the treatment of GCTB of the skull base, with marked reduction in tumor size and a meaningful disease-free interval. 28 Although adjuvant radiation therapy appears to offer a control benefit, Table 1 Giant Cell Tumor of the Lateral Skull Base Gamboa et al. e52 the data are limited by their retrospective nature, small patient numbers, and short follow-up intervals. Given these limitations, general consensus regarding optimal dose and fractionation regimens are lacking. Moreover, there is concern that radiotherapy may contribute to malignant transformation. 20, 25 This risk may be minimized by use of conventional fractionation regimens without compromising tumor control; however, longer follow-up is needed to better characterize this risk.
15,25
Recently, several studies have investigated the role of targeted therapy with denosumab, a fully humanized monoclonal receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, which has shown promise as a potential effective chemotherapeutic treatment option in patients with GCTB. 29 The osteoclastic giant cells responsible for local bony destruction and invasion in GCTB have been shown to ubiquitously express RANK receptor. [29] [30] [31] Current evidence suggests that the neoplastic stromal cells promote the growth, proliferation, and osteolytic activity of the multinucleated osteoclastic giant cells through the overexpression of RANK-L, thus driving local bony destruction. 30, 32 With ongoing clinical trials studying the effectiveness of denosumab in the treatment of GCTBs, the role of monoclonal therapy in GCTBs of the skull base has not yet been fully characterized. 31, 33, 34 Current evidence for the management of GCTBs of the skull recommends complete surgical resection with negative margins to achieve the highest rate of cure and lowest risk of recurrence. 4, 16 Nevertheless, the inhibition of this pathway with a monoclonal RANK-L antibody may limit bony destruction and tumor progression, thereby making these tumors of the lateral skull base more amenable to complete surgical resection and therefore decreasing the morbidity and mortality of this disease.
Conclusion
The skull is a relatively rare location for a GCTB to occur. When this tumor is found, it is normally found in the temporal or sphenoid bones. Although GCTB is a benign tumor, it is also locally aggressive and has the ability to recur or rarely metastasize. Gross total resection is the current treatment of choice in GCTB of the skull, but it can be difficult to achieve due to the proximity of the tumor to important neural and vascular structures. Subtotal resection with adjuvant radiotherapy may be a good alternative treatment in such cases. Although radiotherapy has been the adjuvant therapy of choice in GCTB treatment, recent literature shows that denosumab, a RANK-L antibody, may also prove to be effective in treating the tumor. Future studies should evaluate the efficacy of different adjuvant therapies used to treat partially resected GCTB of the lateral skull base.
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